Caerus US 1 Inc.

Caerus US 1 Inc., a foreign-owned, for-profit entity based in New York that operates as Citeline, supplies pharmaceutical information databases, drug development data, and clinical trial software licenses to federal health agencies as a prime contractor (79% of recent awards) and as a subcontractor on health IT and data analytics programs. The vendor competes exclusively full-and-open with no set-asides across its federal footprint.

Caerus delivers concrete pharmaceutical research and market intelligence capabilities through branded software licenses and database subscriptions. The portfolio centers on TrialTrove (a curated global clinical trials database with biomarker and genomic data fields, supporting the National Cancer Institute's Cancer Data Science Laboratory), Biomedtracker (a comprehensive database of pharmaceutical information including chemicals, royalties, deals, and companies used by the National Center for Advancing Translational Sciences), Pink Sheet and Generics Bulletin (pharmaceutical market intelligence publications supporting regulatory and policy work at the Federal Trade Commission), and Pharmaprojects, Trial Predict, and Trial Trove (Informa Pharma publications supplied to the Office of the Assistant Secretary for Preparedness and Response). Representative prime awards include a $59,900 firm fixed-price purchase order from the National Cancer Institute for TrialTrove software license renewal through February 2029 under FAR Part 12 commercial item procedures, a $247,500 sole-source definitive contract from the Federal Trade Commission for access to MMIT Formulary Analytics, and a $233,207 purchase order from the Office of the Assistant Secretary for Preparedness and Response for renewal licenses to four Informa Pharma publications.

The vendor's customer concentration is tightly held within HHS and the FTC. The top five funding agencies account for 86% of awards by count, led by the National Cancer Institute (4 awards, $136 thousand combined potential value) and the Office of the Assistant Secretary for Preparedness and Response (3 awards, $233 thousand). The Federal Trade Commission anchors the portfolio by potential value ($322 thousand across two awards), while the Food and Drug Administration holds the single largest award at $596 thousand. Recent activity shows moderate growth — one award in 2022 to five in 2024 — followed by a dip to two awards each in 2025 and 2026. Only one award (the FTC Pink Sheet and Generics Bulletin definitive contract worth $74 thousand) faces ultimate completion within the next twenty-four months.

Caerus places two task orders under the Alliant II GWAC and one under a Multiple Award Schedule. The vendor subcontracts to Leidos on HHS Biomedical Advanced Research and Development Authority enterprise IT support (two awards in September 2024 and September 2025) and to Research Triangle Institute on data analytics and program support for the Medicare Prescription Drug Inflation Reduction Act implementation. Combined dollars obligated ($2.4 million) exceed combined potential value ($1.4 million), reflecting contract performance and invoicing patterns above initial ceiling estimates.